Search

Your search keyword '"Wang, Xing-Huan"' showing total 361 results
Start Over Author "Wang, Xing-Huan"
361 results on '"Wang, Xing-Huan"'

4. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)

Author

Jin, Ying-Hui, Zeng, Xian-Tao, Liu, Tong-Zu, Bai, Zhi-Ming, Dou, Zhong-Ling, Ding, De-Gang, Fan, Zhi-Lu, Han, Ping, Huang, Yi-Ran, Huang, Xing, Li, Ming, Li, Xiao-Dong, Li, Yi-Ning, Li, Xu-Hui, Liang, Chao-Zhao, Liu, Jiu-Min, Ma, Hong-Shun, Qi, Juan, Shi, Jia-Qi, Wang, Jian, Wang, De-Lin, Wang, Zhi-Ping, Wang, Yun-Yun, Wang, Yong-Bo, Wei, Qiang, Xia, Hai-Bo, Xing, Jin-Chun, Yan, Si-Yu, Zhang, Xue-Pei, Zheng, Guo-You, Xing, Nian-Zeng, He, Da-Lin, and Wang, Xing-Huan

Published
2022
Full Text
View/download PDF

5. Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition)

Author

Zeng, Xian-Tao, Jin, Ying-Hui, Liu, Tong-Zu, Chen, Fang-Ming, Ding, De-Gang, Fu, Meng, Gu, Xin-Quan, Han, Bang-Min, Huang, Xing, Hou, Zhi, Hu, Wan-Li, Kang, Xin-Li, Li, Gong-Hui, Li, Jian-Xing, Li, Pei-Jun, Liang, Chao-Zhao, Liu, Xiu-Heng, Liu, Zhi-Yu, Liu, Chun-Xiao, Liu, Jiu-Min, Luo, Guang-Heng, Luo, Yi, Qin, Wei-Jun, Qiu, Jian-Hong, Qiu, Jian-Xin, Shang, Xue-Jun, Shi, Ben-Kang, Sun, Fa, Tian, Guo-Xiang, Tian, Ye, Wang, Feng, Wang, Feng, Wang, Yin-Huai, Wang, Yu-Jie, Wang, Zhi-Ping, Wang, Zhong, Wei, Qiang, Xiao, Min-Hui, Xu, Wan-Hai, Yi, Fa-Xian, Zhu, Chao-Yang, Zhuang, Qian-Yuan, Zhou, Li-Qun, Zou, Xiao-Feng, Xing, Nian-Zeng, He, Da-Lin, and Wang, Xing-Huan

Published
2022
Full Text
View/download PDF

14. Aspartoacylase suppresses prostate cancer progression by blocking LYN activation

Author

Weng, Hong, primary, Xiong, Kang-Ping, additional, Wang, Wang, additional, Qian, Kai-Yu, additional, Yuan, Shuai, additional, Wang, Gang, additional, Yu, Fang, additional, Luo, Jun, additional, Lu, Meng-Xin, additional, Yang, Zhong-Hua, additional, Liu, Tao, additional, Huang, Xing, additional, Zheng, Hang, additional, and Wang, Xing-Huan, additional

Published
2023
Full Text
View/download PDF

16. Perceived infection transmission routes, infection control practices, psychosocial changes, and management of COVID-19 infected healthcare workers in a tertiary acute care hospital in Wuhan: a cross-sectional survey

Author

Jin, Ying-Hui, Huang, Qiao, Wang, Yun-Yun, Zeng, Xian-Tao, Luo, Li-Sha, Pan, Zhen-Yu, Yuan, Yu-Feng, Chen, Zhi-Min, Cheng, Zhen-Shun, Huang, Xing, Wang, Na, Li, Bing-Hui, Zi, Hao, Zhao, Ming-Juan, Ma, Lin-Lu, Deng, Tong, Wang, Ying, and Wang, Xing-Huan

Published
2020
Full Text
View/download PDF

18. Additional file 1 of Aspartoacylase suppresses prostate cancer progression by blocking LYN activation

Author

Weng, Hong, Xiong, Kang-Ping, Wang, Wang, Qian, Kai-Yu, Yuan, Shuai, Wang, Gang, Yu, Fang, Luo, Jun, Lu, Meng-Xin, Yang, Zhong-Hua, Liu, Tao, Huang, Xing, Zheng, Hang, and Wang, Xing-Huan

Abstract

Additional file 1: Table S1. Characteristics of patients providing samples for RNA-Seq. Table S2. Characteristics of patients providing samples for Western blotting. Table S3. Characteristics of patients providing samples for IHC. Table S4. Characteristics of patients providing samples for RT-qPCR. Fig. S1. ASPA is down-regulated in PCa patients. Fig. S2. ASPA overexpression inhibits DU145 cell proliferation and migration in vitro. Fig. S3. ASPA knockdown promotes DU145 cell proliferation and migration in vitro. Fig. S4. ASPA negatively regulates JNK1/2-C-Jun activity in PC-3 cells. Fig. S5. LYN mediates the function of ASPA in PC-3 cells.

Published
2023
Full Text
View/download PDF

30. Additional file 1 of Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)

Author

Jin, Ying-Hui, Zeng, Xian-Tao, Liu, Tong-Zu, Bai, Zhi-Ming, Dou, Zhong-Ling, Ding, De-Gang, Fan, Zhi-Lu, Han, Ping, Huang, Yi-Ran, Huang, Xing, Li, Ming, Li, Xiao-Dong, Li, Yi-Ning, Li, Xu-Hui, Liang, Chao-Zhao, Liu, Jiu-Min, Ma, Hong-Shun, Qi, Juan, Shi, Jia-Qi, Wang, Jian, Wang, De-Lin, Wang, Zhi-Ping, Wang, Yun-Yun, Wang, Yong-Bo, Wei, Qiang, Xia, Hai-Bo, Xing, Jin-Chun, Yan, Si-Yu, Zhang, Xue-Pei, Zheng, Guo-You, Xing, Nian-Zeng, He, Da-Lin, and Wang, Xing-Huan

Abstract

Additional file 1. Classification criterion of NMIBC

Published
2022
Full Text
View/download PDF

31. Additional file 1 of Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition)

Author

Zeng, Xian-Tao, Jin, Ying-Hui, Liu, Tong-Zu, Chen, Fang-Ming, Ding, De-Gang, Fu, Meng, Gu, Xin-Quan, Han, Bang-Min, Huang, Xing, Hou, Zhi, Hu, Wan-Li, Kang, Xin-Li, Li, Gong-Hui, Li, Jian-Xing, Li, Pei-Jun, Liang, Chao-Zhao, Liu, Xiu-Heng, Liu, Zhi-Yu, Liu, Chun-Xiao, Liu, Jiu-Min, Luo, Guang-Heng, Luo, Yi, Qin, Wei-Jun, Qiu, Jian-Hong, Qiu, Jian-Xin, Shang, Xue-Jun, Shi, Ben-Kang, Sun, Fa, Tian, Guo-Xiang, Tian, Ye, Wang, Feng, Wang, Yin-Huai, Wang, Yu-Jie, Wang, Zhi-Ping, Wang, Zhong, Wei, Qiang, Xiao, Min-Hui, Xu, Wan-Hai, Yi, Fa-Xian, Zhu, Chao-Yang, Zhuang, Qian-Yuan, Zhou, Li-Qun, Zou, Xiao-Feng, Xing, Nian-Zeng, He, Da-Lin, and Wang, Xing-Huan

Subjects
Data_FILES
Abstract

Additional file 1. Conflict of interest statement form.

Published
2022
Full Text
View/download PDF

32. Additional file 2 of Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition)

Author

Zeng, Xian-Tao, Jin, Ying-Hui, Liu, Tong-Zu, Chen, Fang-Ming, Ding, De-Gang, Fu, Meng, Gu, Xin-Quan, Han, Bang-Min, Huang, Xing, Hou, Zhi, Hu, Wan-Li, Kang, Xin-Li, Li, Gong-Hui, Li, Jian-Xing, Li, Pei-Jun, Liang, Chao-Zhao, Liu, Xiu-Heng, Liu, Zhi-Yu, Liu, Chun-Xiao, Liu, Jiu-Min, Luo, Guang-Heng, Luo, Yi, Qin, Wei-Jun, Qiu, Jian-Hong, Qiu, Jian-Xin, Shang, Xue-Jun, Shi, Ben-Kang, Sun, Fa, Tian, Guo-Xiang, Tian, Ye, Wang, Feng, Wang, Yin-Huai, Wang, Yu-Jie, Wang, Zhi-Ping, Wang, Zhong, Wei, Qiang, Xiao, Min-Hui, Xu, Wan-Hai, Yi, Fa-Xian, Zhu, Chao-Yang, Zhuang, Qian-Yuan, Zhou, Li-Qun, Zou, Xiao-Feng, Xing, Nian-Zeng, He, Da-Lin, and Wang, Xing-Huan

Subjects
InformationSystems_INFORMATIONSTORAGEANDRETRIEVAL, Data_FILES, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

Additional file 2. Literature retrieval strategy.

Published
2022
Full Text
View/download PDF

33. Additional file 3 of Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)

Author

Jin, Ying-Hui, Zeng, Xian-Tao, Liu, Tong-Zu, Bai, Zhi-Ming, Dou, Zhong-Ling, Ding, De-Gang, Fan, Zhi-Lu, Han, Ping, Huang, Yi-Ran, Huang, Xing, Li, Ming, Li, Xiao-Dong, Li, Yi-Ning, Li, Xu-Hui, Liang, Chao-Zhao, Liu, Jiu-Min, Ma, Hong-Shun, Qi, Juan, Shi, Jia-Qi, Wang, Jian, Wang, De-Lin, Wang, Zhi-Ping, Wang, Yun-Yun, Wang, Yong-Bo, Wei, Qiang, Xia, Hai-Bo, Xing, Jin-Chun, Yan, Si-Yu, Zhang, Xue-Pei, Zheng, Guo-You, Xing, Nian-Zeng, He, Da-Lin, and Wang, Xing-Huan

Abstract

Additional file 3. Results of meta-analyses

Published
2022
Full Text
View/download PDF

39. Double-Sheath Vacuum Suction Minimally Invasive Percutaneous Nephrolithotomy for Management of Large Renal Stones.

Author

Wu, Zhong-Hua, Wang, Yong-Zhi, Liu, Tong-Zu, Wang, Xing-Huan, Zheng, Hang, and Zhang, Yin-Gao

Subjects
LASER lithotripsy, KIDNEY stones, PERCUTANEOUS nephrolithotomy, LENGTH of stay in hospitals, BLOOD transfusion
Abstract

Objectives: This study aimed to describe a novel double-sheath vacuum suction minimally invasive percutaneous nephrolithotomy (mini-PCNL) to overcome the deficiencies of the conventional procedure. Patients and Methods: Between March 2019 and December 2019, 65 patients (37 males and 28 females) with a mean age of 41 years (range 23–69) underwent mini-PCNL with double-sheath vacuum suction. It consisted of an F20 Y-shaped sheath as an outer sheath and an F16 Y-shaped sheath as an inner sheath, in which the inner sheath was longer than the outer sheath. The oblique arm of the outer sheath and the inner sheath was connected to the perfusion inflow and the vacuum suction, respectively. A 550-μm holmium-YAG laser was introduced for stone fragmentation through the working channel of the mini-nephroscope, which was no longer connected to the perfusion fluid. Results: All procedures were successful. Mean operation time was 50.2 min (range 39–83). Mean hemoglobin decrease was 5.2 g/L (range 1.0–15.5), and no patient needed a blood transfusion. One patient (1.5%) with low fever (<38°C) at day 1 had returned to normal at day 2 without administration of antibiotics. There were no Clavien grade 2–4 complications. Mean postoperative hospital stay was 2.4 days (range 2–6). The initial stone-free rate of PCNL was 81.53% (53 of 65 patients). One month after surgery, the final stone-free rate increased to 90.77% (59/65 patients). Conclusions: The double-sheath vacuum suction mini-PCNL is a safe and effective modality for large renal stones, which might increase the efficiency of stone extraction with low intrapelvic pressure. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

49. Additional file 2 of Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990���2019

Author

Zi, Hao, He, Shao-Hua, Leng, Xie-Yuan, Xu, Xiao-Feng, Huang, Qiao, Weng, Hong, Zhu, Cong, Li, Lu-Yao, Gu, Jia-Min, Li, Xu-Hui, Ming, Dao-Jing, Li, Xiao-Dong, Yuan, Shuai, Wang, Xing-Huan, He, Da-Lin, and Zeng, Xian-Tao

Abstract

Additional file 2. Fig. S1. Percentage of incident cases, deaths, and DALYs for genitourinary cancers in 1990 and 2019. a Incident cases. b Deaths. c DALYs. DALYs disability-adjusted life-years. Fig. S2. Global ASIR, ASMR, and ASDR of genitourinary cancers from 1990 to 2019. a ASIR. b ASMR. c ASDR. ASIR age-standardized incidence rate, ASMR age-standardized mortality rate, ASDR age-standardized DALYs rate, DALYs disability-adjusted life-years. Fig. S3. EAPC of ASMR for genitourinary cancers in global and 21 regions. a Kidney cancer. b Bladder cancer. c Prostate cancer. ASMR age-standardized mortality rate, EAPC estimated annual percentage change. Fig. S4. EAPC of ASDR for genitourinary cancers in global and 21 regions. a Kidney cancer. b Bladder cancer. c Prostate cancer. ASDR age-standardized DALYs rate, EAPC estimated annual percentage change. Fig. S5. Burden of kidney cancer by SDI quintile from 1990 to 2019. DALYs disability-adjusted life-years, SDI sociodemographic index. Fig. S6. Burden of bladder cancer by SDI quintile from 1990 to 2019. DALYs disability-adjusted life-years, SDI sociodemographic index. Fig. S7. Burden of prostate cancer by SDI quintile from 1990 to 2019. DALYs disability-adjusted life-years, SDI sociodemographic index. Fig. S8. ASMR of kidney cancer for 21 regions and 204 countries and territories by SDI. a 21 regions by SDI from 1990 to 2019. b 204 countries and territories by SDI in 2019. ASMR age-standardized mortality rate, SDI sociodemographic index. Fig. S9. ASDR of kidney cancer for 21 regions and 204 countries and territories by SDI. a 21 regions by SDI from 1990 to 2019. b 204 countries and territories by SDI in 2019. ASDR age-standardized DALYs rate, SDI sociodemographic index. Fig. S10. ASIR of bladder cancer for 21 regions and 204 countries and territories by SDI. a 21 regions by SDI from 1990 to 2019. b 204 countries and territories by SDI in 2019. ASIR age-standardized incidence rate, SDI sociodemographic index. Fig. S11. ASIR of prostate cancer for 21 regions and 204 countries and territories by SDI. a 21 regions by SDI from 1990 to 2019. b 204 countries and territories by SDI in 2019. ASIR age-standardized incidence rate, SDI sociodemographic index. Fig. S12. ASMR of bladder cancer for 21 regions and 204 countries and territories by SDI. a 21 regions by SDI from 1990 to 2019. b 204 countries and territories by SDI in 2019. ASMR age-standardized mortality rate, SDI sociodemographic index. Fig. S13. ASDR of bladder cancer for 21 regions and 204 countries and territories by SDI. a 21 regions by SDI from 1990 to 2019. b 204 countries and territories by SDI in 2019. ASDR age-standardized DALYs rate, SDI sociodemographic index. Fig. S14. ASMR of prostate cancer for 21 regions and 204 countries and territories by SDI. a 21 regions by SDI from 1990 to 2019. b 204 countries and territories by SDI in 2019. ASMR age-standardized mortality rate, SDI sociodemographic index. Fig. S15. ASDR of prostate cancer for 21 regions and 204 countries and territories by SDI. a 21 regions by SDI from 1990 to 2019. b 204 countries and territories by SDI in 2019. ASDR age-standardized DALYs rate, SDI sociodemographic index. Fig. S16. Global incidence, mortality, and DALYs of bladder cancer by age and sex in 2019. DALYs disability-adjusted life-years. Fig. S17. Global incidence, mortality, and DALYs of prostate cancer by age and sex in 2019. DALYs disability-adjusted life-years.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results